

Open Calls for TRANSVAC2 Vaccine Development Services and Trainings: Apply Now!

Vaccine Development Services: Deadline January 15th, 2022

Developing a vaccine is a time-consuming and complex process, requiring a combination of specialized skills and technical capacities not readily available at a single organization. To enable access to these skills and capacities, TRANSVAC2 offers high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use. These services are not restricted to any disease area. **Services will be offered free of charge, with few exceptions.** Academic and non-academic research groups, SMEs and industries can apply!

Are you a researcher? Do you have good preliminary results, but need support to further develop your vaccine candidate? **TRANSVAC2 R&D services might be a perfect match for you!**

The transnational access (TNA) call runs until January 15th, 2022. For further information on services available and how to apply please visit www.transvac.org/transvac2.

Vaccine Training Courses: Deadline December 15th, 2021

TRANSVAC2 also offers **free training courses** to provide fundamental and advanced knowledge on a wide range of **vaccine development-related topics**.

On this call TRANSVAC2 offers free three advanced courses:

- **M3: Adjuvants and Vaccine Formulations** - offered by Vaccine Formulation Institute (VFI)
March 21st-24th in Geneva, Switzerland
- **M5: Statistics of vaccine evaluation** - offered by Biomedical Primate Research Centre (BPRC)
March 28th-April 1st in Rijswijk, Netherlands
- **M14: Regulatory aspects of vaccine development**, - offered by European Infrastructure for Translational Medicine (EATRIS) March 21st-22nd in Amsterdam, Netherlands

Submit your training application at www.transvac.org/transvac2 by December 15th, 2021.

About TRANSVAC2

TRANSVAC2 is a European vaccine research and development (R&D) infrastructure project coordinated by the European Vaccine Initiative (EVI) and dedicated to accelerating the development of safe, effective and affordable vaccines.

TRANSVAC2 has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement N° 730964.

